16th Annual Meeting of the Association for Cancer Immunotherapy (CIMT) - X4 Pharmaceuticals

16th Annual Meeting of the Association for Cancer Immunotherapy (CIMT)

16th Annual Meeting of the Association for Cancer Immunotherapy (CIMT)

May 2018

The safety, tolerability, and preliminary clinical activity of the CXCR4 inhibitor X4P-001 and nivolumab in renal cell carcinoma patients that are refractory to nivolumab monotherapy

© Copyright 2024 X4 Pharmaceuticals. All Rights Reserved. Terms of Use | Privacy | Compliance and Ethics